| Today's Big NewsMar 6, 2023 |
|
Production of these particles, which can protect and deliver medicines and vaccines where they need to go in the body, is increasing. Learn more about how collaborating with a CDMO could be invaluable in developing nano-based systems. Learn more. 
|
|
| By Nick Paul Taylor Incyte’s first bid to build a better Jakafi regimen is banjaxed. A phase 3 trial of parsaclisib and Jakafi has come screeching to a halt ahead of schedule after the independent data monitoring committee found it was on course to fail. |
|
|
|
By Annalee Armstrong Invivyd, which was launched in the early days of the pandemic under the name Adagio to find treatments for COVID-19, is hoping the third monoclonal antibody is the charm. |
By James Waldron What do TCR² Therapeutics and Adaptimmune have in common? They’re both T-cell-focused drug developers that have been shedding staff in recent weeks to stay afloat. |
Sponsored by Syneos Health This story centers on the benefits of implementing a full service commercial model to improve launch success for customers who lack the necessary infrastructure. Watch how Syneos Health expertise in Medical Affairs acted as a bridge to forge this full service commercial partnership, which helped meet critical deadlines for patients. |
|
Thursday, March 23, 2023 | 10am ET / 7am PT In this webinar, we will discuss customer-centric digital innovations that are improving overall process, product quality and performance, as well as transforming CDMO relationships. Register now to learn more! .png)
|
|
By Max Bayer Merck & Co. has looked to its mid-to-late stage cardiovascular pipeline as a potential goldmine amid the race to replace Keytruda's revenue stream. And a handful of new readouts provide a glimpse into the promise the company is banking on. |
By Annalee Armstrong It’s been a year since Novartis ventured into orbit with Voyager Therapeutics to find new central nervous system targets. Now, the Big Pharma is ready to go deeper into space with the AAV capsid discovery biotech. |
By James Waldron Weeks after Atai Life Sciences’ ketamine-like drug failed a phase 2 drug in depression, the mental health-focused company is laying off 30% of staff. |
By Gabrielle Masson Aclaris Therapeutics’ investigational immuno-inflammatory drug has failed to hit efficacy targets in a phase 2a trial, sending the biotech’s stock spiraling. |
By Max Bayer Rallybio is prioritizing version 2.0 of a therapy to treat a fetal and neo-natal blood condition, squashing work on the med’s first iteration as a result. |
By Nick Paul Taylor Harbour BioMed has taken the lead in the Chinese leg of a competitive autoimmune race, becoming the first company to show an anti-FcRn drug improves outcomes in generalized myasthenia gravis in the country. The result is a boost for Immunovant, which has rights to the drug in several major markets. |
By Helen Floersh Scientists have known the genetic mutation behind the rare bone marrow syndrome poikiloderma with neutropenia for some time, but exactly how the mutation causes the condition has remained a mystery. Now, researchers think they’ve cracked the case—and found a potential treatment, too. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Andrea Park CZ Biohub Chicago will focus specifically on developing new technologies equipped with sensors and probes that can draw out high-resolution biological information from human tissue at a molecular level. |
By Fraiser Kansteiner Moderna pinpointed the Harwell Science Campus in Oxfordshire, England, as the home of its upcoming Innovation and Technology Center. The location places Moderna within the U.K.’s biopharma-rich “Golden Triangle” between London, Oxford and Cambridge. |
By Andrea Park As diabetes device makers race to build completely hands-off artificial pancreas systems, Abbott’s continuous glucose monitors are getting a significant upgrade. |
By Zoey Becker After scoring an accelerated approval for Alzheimer's disease drug Leqembi in January, Eisai and Biogen hope to turn that into a traditional approval by July 6. But an advisory committee will get a chance to vote on the drug first. |
By Anastassia Gliadkovskaya The Walgreens decision stems from a letter written by nearly two dozen Republican state attorneys general at the beginning of February that threatened legal action if the company began distributing Mifepristone in their states. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss 2022's M&A trends in the medtech sector and the surprising multibillion-dollar megadeals. We also cover the top headlines from this week. |
|
|---|
|
|
|
May 1-3, 2023 | Jersey City, NJ
Examine how the current changes to field medical will affect the role moving forward. Last chance to save on Early Bird Rates, Register Today! .png)
|
|
Whitepaper Have you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
Research Like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
